跳至主要内容
临床试验/NCT04645134
NCT04645134已完成不适用

Physical Activity and Cognitive Function in Older Adults: A Novel Role for GPLD1

Pennington Biomedical Research Center1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2021年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
1
主要终点
Plasma concentrations of GPLD1

研究概览

简要总结

The investigators are conducting a cross-sectional, observational study to investigate whether plasma GPLD1 concentrations are associated with higher cognitive function and better brain structure and function in two groups of older adults with high or low levels of physical activity.

详细描述

This is a cross-sectional, observational study which will enroll up to 28 healthy, older adults (65-85 y, BMI 20-35 kg/m2), and stratify by current self-reported physical activity level (equal inactive vs. equal highly active).

Aim 1: Investigate whether physical activity level is associated with GPLD1.

Aim 2: Investigate whether cognitive function and brain structure/function are associated with GPLD1.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
65 Years 至 85 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 65-85 y (inclusive)
  • Body mass index (BMI) of 20-35 kg/m2 (inclusive)
  • Willing to have blood and data stored for future research use

排除标准

  • History of clinically diagnosed diabetes (Type 1 or 2) or a fasting blood glucose >126 mg/dL
  • Diagnosed Alzheimer's disease, dementia, or related-brain diseases
  • Chronic use of atypical antipsychotic or bipolar medications
  • Initiation of novel pharmacotherapy agents (such as antidepressant, hypertension, or dyslipidemia) within the last 3 months
  • Uncontrolled hypertension (blood pressure >160 systolic or >110 diastolic)
  • Asthma that limits the ability to participate in moderate to vigorous physical activity or requiring systemic glucocorticoid administration
  • Emphysema that limits the ability to participate in moderate to vigorous physical activity or requiring systemic glucocorticoid administration
  • Current alcohol use exceeding 14 drinks per week in women, exceeding 21 drinks per week in men, having treatment for alcohol abuse in the last year, or having treatment for alcohol abuse more than 1 year ago (but with inability to refrain from alcohol in the past year)
  • Use of illegal drugs or marijuana within 1-month of completing a Screening Visit; treatment for drug addiction in the 1-year or having treatment for drug addiction >1-year ago, but with an inability to refrain from the drug of addiction in the 1-year
  • Unwilling to abstain from illegal drugs and marijuana for the duration of the study
  • Contraindication for MRI (e.g., metal objects, claustrophobia, etc.)
  • Psychotic mental illness (e.g., schizophrenia, bipolar, on-and- off use of anti-psychotic medication)
  • History of cardiovascular disease (or diseases of the heart, lungs, or blood) that limits participation in moderate to vigorous physical activity
  • History of liver, blood, kidney, thyroid or other diseases that limits moderate to vigorous physical activity at the time of enrollment
  • Cancer that limits moderate to vigorous physical activity
  • Treatment with systemic immunosuppressant medication
  • Taking adrenergic stimulants (e.g., amphetamine) or adrenergic blockers (e.g., Propanolol) that will alter metabolic rate
  • Have plans to substantially alter their current level of physical activity over the next 1-month

结局指标

主要结局

Plasma concentrations of GPLD1

时间窗: 1 day

Plasma GPLD1 (by a blood draw) is performed.

次要结局

  • Physical activity level(7 days)
  • Brain activity and function(1 day)
  • Total grey matter volume(1 day)
  • Cognitive function(1 day)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Eric Ravussin

Associate Executive Director for Clinical Science

Pennington Biomedical Research Center

研究点 (1)

Loading locations...

相似试验